Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱(chēng) 貨號(hào) 規(guī)格
Recombinant Proteus mirabilis 5-methyltetrahydropteroyltriglutamate--homocysteine methyltransferase (metE), partial CSB-YP465383EYZ
CSB-EP465383EYZ
CSB-BP465383EYZ
CSB-MP465383EYZ
CSB-EP465383EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Sulfurtransferase TusA (tusA) CSB-YP465384EYZ
CSB-EP465384EYZ
CSB-BP465384EYZ
CSB-MP465384EYZ
CSB-EP465384EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis HTH-type transcriptional regulator BetI (betI) CSB-YP465385EYZ
CSB-EP465385EYZ
CSB-BP465385EYZ
CSB-MP465385EYZ
CSB-EP465385EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis D-amino acid dehydrogenase small subunit (dadA) CSB-YP465386EYZ
CSB-EP465386EYZ
CSB-BP465386EYZ
CSB-MP465386EYZ
CSB-EP465386EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Probable crotonobetaine/carnitine-CoA ligase (caiC), partial CSB-YP465387EYZ
CSB-EP465387EYZ
CSB-BP465387EYZ
CSB-MP465387EYZ
CSB-EP465387EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis DnaA-homolog protein hda (hda) CSB-YP465388EYZ
CSB-EP465388EYZ
CSB-BP465388EYZ
CSB-MP465388EYZ
CSB-EP465388EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Lipid A palmitoyltransferase PagP (pagP) CSB-YP465389EYZ
CSB-EP465389EYZ
CSB-BP465389EYZ
CSB-MP465389EYZ
CSB-EP465389EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis LexA repressor (lexA) CSB-YP465390EYZ
CSB-EP465390EYZ
CSB-BP465390EYZ
CSB-MP465390EYZ
CSB-EP465390EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis NADH-quinone oxidoreductase subunit N (nuoN), partial CSB-YP465391EYZ
CSB-EP465391EYZ
CSB-BP465391EYZ
CSB-MP465391EYZ
CSB-EP465391EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis DNA-directed RNA polymerase subunit omega (rpoZ) CSB-YP465392EYZ
CSB-EP465392EYZ
CSB-BP465392EYZ
CSB-MP465392EYZ
CSB-EP465392EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis NADH-quinone oxidoreductase subunit I (nuoI) CSB-YP465393EYZ
CSB-EP465393EYZ
CSB-BP465393EYZ
CSB-MP465393EYZ
CSB-EP465393EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Erythronate-4-phosphate dehydrogenase (pdxB) CSB-YP465394EYZ
CSB-EP465394EYZ
CSB-BP465394EYZ
CSB-MP465394EYZ
CSB-EP465394EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Coproporphyrinogen-III oxidase, aerobic (hemF) CSB-YP465395EYZ
CSB-EP465395EYZ
CSB-BP465395EYZ
CSB-MP465395EYZ
CSB-EP465395EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Putative N-acetylmannosamine-6-phosphate 2-epimerase (nanE) CSB-YP465396EYZ
CSB-EP465396EYZ
CSB-BP465396EYZ
CSB-MP465396EYZ
CSB-EP465396EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Phosphoenolpyruvate carboxykinase [ATP] (pckA), partial CSB-YP465397EYZ
CSB-EP465397EYZ
CSB-BP465397EYZ
CSB-MP465397EYZ
CSB-EP465397EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Protein viaA (viaA) CSB-YP465398EYZ
CSB-EP465398EYZ
CSB-BP465398EYZ
CSB-MP465398EYZ
CSB-EP465398EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Ribose-5-phosphate isomerase A (rpiA) CSB-YP465399EYZ
CSB-EP465399EYZ
CSB-BP465399EYZ
CSB-MP465399EYZ
CSB-EP465399EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Chromosomal replication initiator protein DnaA (dnaA) CSB-YP465400EYZ
CSB-EP465400EYZ
CSB-BP465400EYZ
CSB-MP465400EYZ
CSB-EP465400EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Nucleoid occlusion factor SlmA (slmA) CSB-YP465401EYZ
CSB-EP465401EYZ
CSB-BP465401EYZ
CSB-MP465401EYZ
CSB-EP465401EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Proteus mirabilis Formamidopyrimidine-DNA glycosylase (mutM) CSB-YP465402EYZ
CSB-EP465402EYZ
CSB-BP465402EYZ
CSB-MP465402EYZ
CSB-EP465402EYZ-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過(guò)多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開(kāi)發(fā)過(guò)程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長(zhǎng)度(全長(zhǎng)或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來(lái)自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開(kāi)發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來(lái)產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過(guò)多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過(guò)程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來(lái)選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見(jiàn)問(wèn)題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問(wèn),涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>